Literature DB >> 3534516

One month's insulin treatment of type II diabetes: the early and medium-term effects following insulin withdrawal.

M J Gormley, D R Hadden, R Woods, B Sheridan, W J Andrews.   

Abstract

In order to see if subcutaneous insulin treatment of type II diabetes might produce lasting physiologic changes, ten patients received one month's insulin treatment under strict dietary supervision. When compared to the pretreatment period, 48 hours after discontinuing insulin treatment fasting plasma glucose had fallen (P = 0.005), fasting serum insulin had risen (P = 0.005), and fasting hepatic glucose production measured by 3H-3-glucose turnover had fallen (P = 0.008). The metabolic clearance rate of glucose measured with the glucose clamp rose significantly after treatment at insulin infusion rates of 40 mU m-2 min-1 (P = 0.015) and 400 mU m-2 min-1 (P = 0.012). The serum insulin and C-peptide responses to oral glucose improved after the treatment in association with the improvement in glucose tolerance, but the plasma glucose response was unchanged. Six other type II diabetic patients who received only dietary supervision did not show significant changes in these variables. Six weeks after discontinuing insulin, the patients' fasting hepatic glucose production was still reduced compared to pretreatment (P = 0.028) and insulin action was still improved at both the lower (P = 0.028) and the higher (P = 0.028) insulin infusion rates, but the fasting plasma glucose and insulin and C-peptide responses to oral glucose had returned to pretreatment values. The improvement in glucose tolerance and beta-cell function induced by insulin treatment seems to be of more limited duration than the improvements in basal hepatic glucose production and in insulin action.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3534516     DOI: 10.1016/0026-0495(86)90039-9

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

Review 1.  The biochemistry of diabetes.

Authors:  R Taylor; L Agius
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

2.  Inhibition of obesity-induced hepatic ER stress by early insulin therapy in obese diabetic rats.

Authors:  Weiping Sun; Yan Bi; Hua Liang; Mengyin Cai; Xiang Chen; Yanhua Zhu; Ming Li; Fen Xu; Qiuqiong Yu; Xiaoying He; Jianping Ye; Jianping Weng
Journal:  Endocrine       Date:  2010-11-19       Impact factor: 3.633

Review 3.  Insulin pump for type 2 diabetes: use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes.

Authors:  Yves Reznik; Ohad Cohen
Journal:  Diabetes Care       Date:  2013-08       Impact factor: 19.112

4.  Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial.

Authors:  R Aronson; Y Reznik; I Conget; J A Castañeda; S Runzis; S W Lee; O Cohen
Journal:  Diabetes Obes Metab       Date:  2016-03-22       Impact factor: 6.577

Review 5.  The OPT2MISE Study - A Review of the Major Findings and Clinical Implications.

Authors:  Yves Reznik; Michael Joubert
Journal:  Eur Endocrinol       Date:  2015-08-19

6.  Diverse endocrine presentations of the syndrome of acanthosis nigricans and insulin resistance.

Authors:  A B Atkinson; L Kennedy; W J Andrews; B Burke; D R Hadden; C M Ritchie; B Sheridan; A I Traub; K Walshe
Journal:  J R Coll Physicians Lond       Date:  1989-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.